Adimab Acquires Rights to Genetastix Yeast Antibody Patents
Adimab, Inc., a pioneer in the integration of antibody discovery, maturation and biomanufacturing, announces the acquisition of the Genetastix (Palo Alto, CA) patent portfolio. Under the agreement the two companies have entered into an exclusive agreement by which Genetastix will assign all its method patents related to antibody discovery in yeast to Adimab, Inc. The financial terms of the agreement were not disclosed but are consistent with Adimab’s business model of reducing the excessive royalty stacking associated with current antibody discovery platforms.
“Genetastix was an early pioneer in yeast-based antibody discovery and we felt that their strong IP position in yeast based antibody discovery and library design would complement our scientific and patent strategy,” says Tillman Gerngross, Adimab co-founder, and CEO.
Lead scientist and founder of Genetastix, Li Zhu, explains, “seeing how fast the Gerngross/Wittrup team was moving their antibody discovery platform into practice, we felt that they will be the team that will make human antibody discovery in yeast a commercial reality. We were excited to join their effort.” Li Zhu will continue to serve as a consultant to Adimab.
About Adimab, Inc.
Adimab is changing the discovery, maturation and production of therapeutic human antibodies. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab can rapidly select for high affinity antibodies that also behave well in a formulation and manufacturing context. Our proprietary library design and presentation technology allows us to discover full-length human antibodies with broad epitope coverage and high affinity faster than any current technology.
Errik B. Anderson
VP Operations & Finance